ASCO 2023 | Comparing responders and non-responders for the loss of function NOD2 mutations

Megan Babette Barnet, MD, The Kinghorn Cancer Centre, Darlinghurst, Australia, summarizes the findings of a trial where whole genome sequencing was used on prospectively recruited patients with lung cancer. Exceptional responders, who did not reach progression-free survival (PFS) and had an immune-related adverse event, were compared with non-responders. Within the exceptional responder’s cohort, 40 patients had established loss of function mutation in NOD2, compared with non-responders where this figure was significantly lower. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.